Prophylactic use of Rh D immunoglobulin in pregnancy care

In 2016, the NBA undertook a scoping exercise to identify clinical guidance published since the 2003 release of Australia’s Guidelines on the Prophylactic Use of Rh D Immunoglobulin (Anti-D) in Obstetrics (817.35 KB), to ensure that Australia’s clinical guidance and antenatal prophylaxis program continued to reflect current evidence and best clinical practice. 

The scoping exercise found a number of international guidelines on the prophylactic use of Rh D immunoglobulin had been published since 2003. 

It was decided that the NBA and the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) should collaborate to develop a new Guideline on the prophylactic use of Rh D immunoglobulin in pregnancy care in accordance with current evidence and consensus among clinical experts.  

A multidisciplinary Expert Reference Group (ERG) with expertise from a range of clinical settings was established to develop the new guideline for health care professionals involved in the management of pregnant Rh D negative women.

The ERG has completed the draft Guideline on the prophylactic use of Rh D immunoglobulin in pregnancy care. It is currently under review. 

The Guidelines on the Prophylactic Use of Rh D Immunoglobulin (Anti-D) in Obstetrics (2003) (817.35 KB) and the Expert Panel Consensus Position Statement regarding the use of Rh(D) immunoglobulin in patients with a Body Mass Index ≥30 (94.33 KB) (2015) remain available to guide practice. 

For more information please email guidelines@blood.gov.au